Autologous Anti-CD20 CAR T-cells C-CAR066 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses Autologous Anti-CD20 CAR T-cells C-CAR066 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2019 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
Janssen Research & Development, LLC (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Shanghai Tongji Hospital, Tongji University School of Medicine (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Autologous Anti-CD20 CAR T-cells C-CAR066.
- Jan 2027A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)Phase 1 · Janssen Research & Development, LLC
Studies
Open first, then newest update. How each study uses Autologous Anti-CD20 CAR T-cells C-CAR066 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)Active, not recruitingPhase 1Janssen Research & Development, LLCNCT05784441Written as JNJ-90009530How we know
- A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T TherapyCompletedPhase 1Institute of Hematology & Blood Diseases Hospital, ChinaNCT04316624Written as C-CAR066How we know
- A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T TherapyCompletedPhase 1Shanghai Tongji Hospital, Tongji University School of MedicineNCT04036019Written as CD20-directed CAR-T cells with CliniMACS Prodigy® systemHow we know